Enovis Co. (NYSE:ENOV) Shares Bought by Artemis Investment Management LLP

Artemis Investment Management LLP grew its position in shares of Enovis Co. (NYSE:ENOV) by 35.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 665,868 shares of the company’s stock after buying an additional 174,116 shares during the period. Artemis Investment Management LLP’s holdings in Enovis were worth $29,218,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Diamond Hill Capital Management Inc. raised its holdings in Enovis by 7.8% during the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company’s stock worth $129,352,000 after purchasing an additional 218,660 shares in the last quarter. Royce & Associates LP increased its position in Enovis by 16.8% during the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock worth $103,479,000 after purchasing an additional 346,317 shares during the period. State Street Corp raised its stake in shares of Enovis by 4.3% during the 3rd quarter. State Street Corp now owns 1,647,220 shares of the company’s stock worth $70,913,000 after buying an additional 68,190 shares in the last quarter. River Road Asset Management LLC purchased a new position in shares of Enovis during the 3rd quarter worth approximately $51,341,000. Finally, Magnetar Financial LLC lifted its holdings in shares of Enovis by 66.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company’s stock valued at $49,937,000 after buying an additional 442,051 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV stock opened at $46.68 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The business has a fifty day simple moving average of $45.85 and a 200-day simple moving average of $44.35.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. During the same period last year, the firm posted $0.56 EPS. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. On average, analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ENOV shares. Evercore ISI dropped their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a report on Tuesday, October 1st. JMP Securities assumed coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.